TruSpine Technologies PLC Funding Loan and Directorate Change (2186R)
February 28 2023 - 1:00AM
UK Regulatory
TIDMTSP
RNS Number : 2186R
TruSpine Technologies PLC
28 February 2023
28 February 2023
TruSpine Technologies plc
("TruSpine" or the "Company")
Funding Loan and Directorate Change
TruSpine Technologies Plc, the medical device company focused on
the spinal (vertebral) stabilisation market, announces that it has
entered into a GBP200,000 loan agreement (the "Loan Agreement").
The Loan Agreement is in addition to the bridging loan facility and
non-binding letter of intent for equity financing set out in the
announcement of 3 January 2023 with the lender of the Loan
Agreement being a separate third-party.
Loan Agreement
Pursuant to the Loan Agreement, the Company received GBP200,000
on 27 February 2023 ("Funding Loan") which will be utilised for
general working capital purposes.
The Funding Loan bears an interest rate of 12 per cent. per
annum starting from the date on which the funds were received by
the Company and ending upon full repayment of the Funding Loan with
accrued interest. Should the Funding Loan not be re-paid by 31 July
2023, the interest rate will adjust to 20 per cent. per annum.
On repayment of the Funding Loan, the Company will issue a
warrant over 8,000,000 new ordinary shares in the Company with an
exercise price of 2.5 pence per share, this warrant will expire on
the second anniversary from the date of issue. A further
announcement will be made in due course.
Directorate Change
The Company also announces that Ian Roberts has resigned from
his role as a director (Chief Executive Officer) of the Company
with immediate effect, but will continue as an employee of the
Company.
Appointment of acting Managing Director
Laurence Strauss has been appointed as acting Managing Director
(non-board appointment). Mr. Strauss started his career in 1986
working in the City and built a private client broking business. He
left the City in 1992, serving as a director of an electrical
contracting business and overseeing its expansion, following which
he replicated the growth model in another business. More recently,
Mr. Strauss has been advising private clients on equity investments
and initial public offerings.
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation, and the Directors of the Company
are responsible for the release of this announcement.
Enquiries:
TruSpine Technologies Plc Tel: +44 (0)20 3638 5025
Laurence Strauss, acting Managing Director
Cairn Financial Advisers LLP (AQSE Corporate Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Ludovico Lazzaretti
Oberon Capital (Joint Broker)
Tel: +44 (0)20 3179 5300
Mike Seabrook / Chris Crawford
Peterhouse Capital Limited (Joint Broker & Financial Adviser)
Tel: +44 (0)20 7469 0930
Lucy Williams / Duncan Vasey
Walbrook PR (Financial PR & IR) Tel: +44 (0) 20 7933 7870 or +44 (0) 7876 741 001
Anna Dunphy truspine@walbrookpr.com
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward-looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXFFFLFFSIDFIV
(END) Dow Jones Newswires
February 28, 2023 02:00 ET (07:00 GMT)
TruSpine Technologies (AQSE:TSP)
Historical Stock Chart
From Dec 2024 to Jan 2025
TruSpine Technologies (AQSE:TSP)
Historical Stock Chart
From Jan 2024 to Jan 2025